Persistent Systems · risk themes across the available quarters.
Bear-case history
Management acknowledged the healthcare sector has been impacted by decisions under the new US administration, particularly affecting scientific instruments, medical devices, and research-oriented customers with grants. While pipeline remains good, execution risk exists as customers optimize costs in response to funding pressures.
Merit increments effective October 1, 2025 will impact Q3 margins by 180 basis points, with only 80-100 basis points expected to be offset through offshoring, utilization management, subcontractor rationalization, SG&A optimization, and ESOP cost reduction. This leaves a net ~80-100bps margin headwind for Q3.
Software license costs surged to ~6-7% of revenue from historical ~2.5-3% due to a large multi-year customer commitment that is now ending. Management noted the industry shift toward 'service as software' bundling makes future normalization unclear—rates could stay at 6% or increase further depending on AI transformation deal structures.
An analyst raised concern about potential pricing deflation as clients demand productivity benefits from AI implementations. Management responded that the issue is 'scope inflation/deflation' rather than per-unit pricing pressure, and noted billing rates are 'fairly consistently moving up.' However, the AI monetization model remains nascent.
While 150bps of margin expansion came from AI platform monetization this quarter, management explicitly stated they are not targeting further significant margin expansion from this source. The sustainability of these benefits depends on continued deal flow and competitive differentiation as peers build similar tools.
Not available
Top 100 customers contribute 82% of revenue and grew at 20%+ YoY. While demonstrating strong account penetration, any slowdown in these relationships could disproportionately impact overall growth trajectory.
Not available